Equities

Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret A

ANGEN.E:IST

Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret A

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TRY)11.98
  • Today's Change-0.25 / -2.04%
  • Shares traded1.82m
  • 1 Year change-9.17%
  • Beta--
Data delayed at least 15 minutes, as of Jun 07 2024 16:09 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS is a Turkey-based company, which is s a biotechnology company operating in accordance with ISO 9001, ISO 13485 and 98/79/EC Total Quality Systems. The Company's main activities are to develop and produce Real-Time Polymerase Chain Reaction (Real-Time PCR) kits, and to create a complete solution with automatic nucleic acid isolation devices and Real-Time PCR Systems. The main goals of the entity are to reduce Turkey's foreign dependency in molecular diagnostics and biotechnology and to gain success in the global market by developing and producing molecular genetic products.

  • Revenue in TRY (TTM)163.74m
  • Net income in TRY122.57m
  • Incorporated2010
  • Employees183.00
  • Location
    Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AEgitim Mah. Kasap Ismail Sk. No:10/23ISTANBUL 34722TurkeyTUR
  • Phone+90 2 163300455
  • Fax+90 2 163300042
  • Websitehttps://www.anatoliageneworks.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
AFYREN SA117.96m-334.65m2.37bn122.00--1.10--20.10-0.3696-0.36960.13032.370.0435--5.3927,696.72-12.35-9.58-13.42-10.4692.6395.57-283.69-162.61---1.620.0719---2.23---4.20------
BIOTON SA1.50bn-21.28m2.45bn358.00--0.5049.271.64-0.0306-0.03062.157.000.22911.006.74516,050.30-0.3261-1.99-0.3999-2.4734.7745.33-1.42-8.610.1841.160.0933---22.10-5.5160.10-38.690.3284--
Captor Therapeutics SA130.80m-532.45m2.49bn104.00--5.68--19.06-15.07-15.073.6312.860.1741--5.14155,413.50-70.87---89.64--54.29---407.07------0.0458--44.15---96.65------
Cantargia AB0.00-739.08m2.53bn23.00--6.20-----1.40-1.400.000.72390.00----0.00-83.14-55.08-107.52-61.35------------0.00------24.69------
AB Science SA33.86m-418.40m2.54bn53.00------74.95-0.2492-0.24920.0195-0.41110.03930.96724.8918,301.89-48.58-65.95-316.31-515.1760.5288.41-1,235.57-1,148.981.02-12.17----1.25-10.6311.97---6.55--
Apontis Pharma AG1.29bn-328.26m2.56bn177.00--2.34--1.99-1.10-1.104.373.690.6823.0115.40208,835.00-15.87---18.25--63.77---23.27--2.63--0.1658---33.67---520.38------
Synthaverse SA489.72m29.31m2.62bn239.0096.183.1231.595.350.05160.05160.86051.590.26011.673.18253,192.501.563.531.834.3260.3955.625.989.590.87233.320.4038--16.3212.66-21.76--111.77--
BenevolentAI SA301.07m-2.60bn2.64bn248.00--0.5821--8.76-0.6321-0.63210.07320.90950.0473--0.363134,774.39-40.88---48.87-------863.69------0.048---30.58--61.38------
Alligator Bioscience AB170.13m-762.77m2.65bn55.00------15.57-0.4848-0.48480.0999-0.07720.5289--8.07956,741.40-237.13-73.26---91.33-----448.35-811.68---104.20----62.7816.60-28.53---20.34--
Anatolia TaniveBytklj Unli Ar Ge SiveTiA163.74m122.57m2.70bn183.0012.913.3217.9016.470.94980.94980.9933.700.1920.43612.38992,388.1014.37--14.98--71.92--74.86--10.57--0.0206---34.45---23.76------
Poolbeg Pharma PLC0.00-161.63m2.77bn8.00--4.66-----0.0079-0.00790.000.02890.00----0.00-22.65---24.00--------------0.00------16.11------
Cantourage Group SE-3.49tn-3.49tn2.92bn2.00--1.89----------3.72----------------------------0.00--------------
4Sc AG10.61m-287.55m2.96bn15.00--16.22--279.06-0.8144-0.81440.03010.49950.0236--3.6820,266.67-63.84-39.49-77.78-42.8468.7592.24-2,709.54-337.74----0.00---30.28-40.7842.64---56.05--
BioPorto A/S151.51m-251.85m2.97bn27.00--15.20--19.58-0.1501-0.15010.09030.10990.41323.667.331,044,452.00-68.68-71.10-100.20-96.5568.0863.38-166.23-239.222.36--0.1354--6.873.5425.81---51.56--
Vistin Pharma ASA1.32bn169.82m3.03bn77.0017.823.3713.532.291.271.279.886.701.112.317.445,692,663.0014.281.7318.932.1159.9358.9212.832.360.853632.960.0934--51.3516.951,066.84---0.1922--
Data as of Jun 07 2024. Currency figures normalised to Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret A's reporting currency: Turkish Lira TRY

Institutional shareholders

0.31%Per cent of shares held by top holders
HolderShares% Held
Union Bancaire Priv�e, UBP SA (UK)as of 25 Jan 2023323.85k0.15%
Dimensional Fund Advisors LPas of 09 May 2024236.54k0.11%
Polunin Capital Partners Ltd.as of 30 Jun 2023128.33k0.06%
DFA Australia Ltd.as of 31 Dec 20231.92k0.00%
American Century Investment Management, Inc.as of 09 May 2024390.000.00%
Schroder Investment Management Ltd.as of 31 Dec 20230.000.00%
More ▼
Data from 31 Jan 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.